Previous 10 | Next 10 |
2023-08-08 17:29:56 ET Regulus Therapeutics press release ( NASDAQ: RGLS ): Q2 GAAP EPS of -$0.37 beats by $0.04 . As of June 30, 2023, Regulus had $37.3 million in cash and cash equivalents. The Company expects its cash runway to extend into mid-2024. For furthe...
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates PR Newswire First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 ...
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire SAN DIEGO , Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of ...
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference PR Newswire SAN DIEGO , July 18, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of in...
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , June 27, 2023 /PRNewswire/ -...
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors PR Newswire SAN DIEGO , June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development o...
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital PR Newswire Program advances to lead compound evaluation in preclinical in vivo models Preliminar...
Regulus Therapeutics Strengthens Research & Development Leadership Regulus Therapeutics Strengthens Research & Development Leadership PR Newswire Appoints Preston S. Klassen, M.D., as President and Head of Research & Development Curtis A. Monn...
Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Blinded safety data observed so far are encouraging SAN DIEGO , ...
2023-05-11 17:15:57 ET Regulus Therapeutics press release ( NASDAQ: RGLS ): Q1 GAAP EPS of -$0.42 beats by $0.02 . As of March 31, 2023, Regulus had $30.3 million in cash and cash equivalents. Combined with the $15.0 million private placement in April, the Company expe...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...